* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced
Dish of the day
Admissions:
None
Delistings:
None
What’s baking in the oven? **
Potential**** Initial Public Offerings:
European Green Transition **** is developing a portfolio of green economy assets in Europe which aims to capitalise on the opportunity created by the green energy transition and announces its intention to conduct a fundraise and to list its ordinary shares on AIM. The Company intends to implement a disciplined M&A focused model and has already acquired a portfolio of assets, notably their principal Olserum Rare Earth Element (REE) project.
Reverse Takeovers:
None
Change of Market:
None
Banquet Buffet***
Aquis Exchange 336p £100.8m (AQX.L)
A creator and facilitator of next-generation financial markets, announce its audited results for the year ended 31 December 2023. Net revenue increased 13% to £22.7m (FY22: 20.1m), as a result, profit before tax increased 15% to £5.2m (FY22: £4.5m). The Company has cash equivalents of £14.8m Aquis Stock Exchange admitted 16 new companies in 2023 - the most of any growth exchange in the UK for the second year running.
Avacta Group 53.75p £188.4m (AVCT.L)
A life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announce that yesterday the third patient was dosed in the first cohort of the two-weekly Phase 1a dose escalation study of its lead pre|CISIONTM drug AVA6000, a peptide drug conjugate designed to target the release of the chemotherapy doxorubicin to tumor tissue. AVA6000 improved the safety and tolerability of doxorubicin and that AVA6000 is showing encouraging preliminary clinical signs of anti-tumor activity. The safety and tolerability of AVA6000 are continuing to be assessed in a Phase 1a dose escalation study.
Eco Animal Health 88p £59.6m (EAH.L)
A animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces an update on trading and business progress for the year ending 31 March 2024. Revenue for the fourth quarter and second half of the year ending 31 March 2024, was in line with expectations, and expects FY revenues to further be in line with expectations. The Company continues to invest in developing its R&D pipeline, focusing on its late stage Mycoplasma vaccines for poultry and vaccines for swine. ECO recently announced that it had received trademark approval for the ECOVAXXIN® family across the EU, USA and the UK.
Feedback Group 120p £16.0m (FDBK.L)
The clinical infrastructure specialist, announces that it has secured funding of £50k for a further Community Diagnostic Centre (CDC) pathway pilot with the Oldham CDC, run by the Northern Care Alliance. This follows the two pilot sites, Amersham CDC in Buckinghamshire and across Buckinghamshire, Oxfordshire and Berkshire ICS. On completion of the initial milestones, the Company will support Oldham CDC to apply for more funding from the 2024-25 NHS budget to extend the pilot with a view to installing Bleepa and establishing a live breathlessness pathway for patients.
Intercede Group 97.5p £56.8m (IGP.L)
The cybersecurity software company specialising in digital identities, has released the latest iteration of its Multi-Factor Authentication MyID MFA product, version 5 (MyID MFA v5). MyID MFA v5 allows organisations to leverage FIDO Passkeys and incorporates Identity Provider (IDP) capabilities. MyID MFA v5 integrates with MyID CMS, providing a centralised management platform for all user credentials and life cycle management.
OPG Power Ventures 10.65p £42.7m (OPG.L)
The developer and operator of power generation assets in India, announces the sale of the Group's 31% equity holding in the four solar assets totalling 62 MW located in Karnataka, India. The Group's 31% interest in each asset is being sold for a total consideration of approximately £291k. This compares to an original investment by the Group in these assets of approximately £2.1k.
Physiomics* 1.35p £1.8m (PYC.L)
A mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its interim results via Investor Meet Company and has updated its website with the presentation. The presentation and Q&A from the meeting are now available at the Company's website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-interim-results-and-company-update/.
Silver Bullet Data Services Group 160p £27.9m (SBDS.L)
A provider of AI driven digital transformation services and products, announce new contract wins and renewals worth, in aggregate, £1.7m. Silverbullet has secured a renewed contract with Heineken, to support in the design, deployment, execution, and measurement of data-driven consumer experiences. In addition, the Company has successfully renewed its 2023 contract and secured a new contract with Greene King to implement technology that enables enhanced personalisation for customers and supports the growth of its digital transformation programme.
ValiRx 3.78p £5.0m (VAL.L)
A life sciences company focusing on early-stage cancer therapeutics and women's health, announces an evaluation agreement with Imperial College London (Agreement). The Agreement specifically focuses on investigating a lead series of dual-kinase inhibitor candidates that show promise in reversing resistance to current standard of care therapeutics in ovarian and other types of cancer. The evaluation process for this project is expected to take approximately 12 months
4basebio 985p £126m (4BB.L)
An provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that the Company’s client, Helix Nanotechnologies Inc. has received HREC approval to progress into a Phase I clinical trial in Australia with HN-0001, an mRNA vaccine generated from 4basebio’s synthetic DNA, opDNA™. 4basebio will continue to support HelixNano with the manufacture of GMP synthetic DNA planned for later in 2024.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.